Isolate Social CBD Tincture Drops. Of all the many reasons that people seek out Isolate CBD drops today, the most common is pain. CBD is effective for most forms of chronic pain, as well as many forms of acute or short-term pain. Many studies have shown the endocannabinoid system’s role in the processing of pain signals. CBD does not directly stimulate the CB1 receptors that are involved in pain perception (THC does), but it does have potent anti-inflammatory benefits, making it a great candidate for treating many types of pain.
Isolate Social CBD Lemon Tincture Drops, Lavender, Peppermint
It can be used to reduce inflammation at the site of injury (a sprained ankle, for example), or for chronic pain caused by pinched, irritated, or injured nerves (called neuropathy).
Review assessed how well CBD works to relieve chronic pain. The review looked at studies conducted between the late 1980s and 2007. Based on these reviews, researchers concluded CBD was effective in overall pain management without adverse side effects. They also noted that CBD was beneficial in treating insomnia related to chronic pain
Seizure Disorders, CBD Drops
CBD has gained much of its notoriety because of the almost-miraculous results it has produced for many sufferers of epilepsy and other seizure disorders, especially in children. Many children with a seizure disorder have tried several different pharmaceuticals, and varying combinations thereof. The side effects of these drugs can include dependency, over-sedation, and cognitive impairment. In some cases, patients have what is called intractable epilepsy, which means that pharmaceutical drugs just don’t work.
This is where CBD has really shone. Charlotte Figi, a young girl with intractable epilepsy featured in Dr. Sanjay Gupta’s documentary series Weed (2013), brought national attention to the unquestionable benefit CBD can have for seizure disorders. She was also the inspiration for the hemp-based CBD product line called Charlotte’s Web.
Cannabidiol as an epileptic treatment has been of interest to researchers since the 1970s. Though studies conducted then and into the ’80s aren’t generally regarded as scientifically solid, the results in human and animal subjects were promising. Several studies support the idea that endocannabinoid deficiency may play a role in the development of seizures.
According to a recent literature review, since 2013, 10 epilepsy centers in America have conducted research regarding the efficacy of cannabis to treat epilepsy. In most studies, trial doses of CBD were 2 to 5 mg/kg/day. Several such studies have shown that CBD does have efficacy for treatment of epilepsy. Reported adverse effects of CBD were mostly mild, including drowsiness, diarrhea, and decreased appetite. The review also underscored that further research is needed to understand the various mechanisms of CBD’s antiepileptic action.
A 2013 study in Colorado of 11 patients found that all of them reported reduced frequency in seizures, with 73% reporting a near-complete, if not complete, reduction.127 A 2015 survey of 117 parents by pediatric neurologists at the UCLA Medical Center showed that 85% of parents reported a decrease in frequency in their children’s seizures, while 14% reported their children were seizure free.
A small clinical study from 2017 enrolled five patients suffering from Sturge-Weber syndrome, a neurological disorder marked by a distinctive port-wine stain on the forehead, scalp, or around the eye.129 Over the 14 weeks of study, three of five had a greater than 50% reduction in seizures, and three remained on CBD long term after the study was completed. Another literature review conducted in 2017 confirmed CBD’s antiepileptic properties and pointed to GW Pharmaceuticals’ successful Phase III trials of Epidiolex (a CBD-dominant pharmaceutical-grade liquid cannabis medicine) as “pivotal evidence of clinical efficacy” of CBD.
Epidiolex was approved by the FDA in June 2018 and has gained state-level approval in Colorado, though at the time of writing CBD was still being considered for re-classification by the Drug Enforcement Agency (DEA). In order for Epidiolex to be put onto the market and become available to patients, the DEA would need to reclassify CBD from a Schedule I to a Schedule II or III controlled substance.